Amir Goldkorn

Assistant Professor

Areas of treatment:

Genitourinary Malignancies


  • Oncology


  • Department of Medicine


  • English

Amir Goldkorn, MD

Assistant Professor

Practicing location:

  • USC Healthcare Center 2

About this doctor:

Amir Goldkorn, M.D. is an assistant professor of medicine at the Keck School of Medicine. Dr. Goldkorn is board certified in medical oncology and internal medicine, and he specializes in genitourinary (GU) malignancies – cancers of the prostate, bladder, kidney, and testis. Dr. Goldkorn completed his undergraduate studies at Harvard University, graduating magna cum laude. He pursued his graduate medical studies at the University of California, Los Angeles (UCLA). After completing his internal medicine residency and board certification at UCLA, he pursued a clinical hematology/oncology fellowship at the University of California, San Francisco (UCSF), where he sub-specialized in the treatment of GU malignancies and completed a postdoctoral research fellowship with Elizabeth Blackburn in the field of telomerase and cancer. At USC, Dr. Goldkorn cares for patients with advanced GU malignancies, and he participates as an investigator in several ongoing clinical trials at Norris Comprehensive Cancer Center. Dr. Goldkorn’s laboratory-based research program is focused on developing the therapeutic and prognostic potential of circulating tumor cells, cancer stem cells, and telomerase – three research areas that offer unique opportunities to better understand and surmount cancer heterogeneity. Circulating tumor cells (CTCs) are cancer cells shed by solid tumors into the bloodstream, and their analysis can address cancer heterogeneity by identifying molecular drivers unique to an individual patient’s tumor. Dr. Goldkorn’s group has developed new technology platforms for capturing CTCs and founded a CTC Research Core at USC Norris, where CTCs are enriched from cancer patient blood samples and molecularly characterized to identify cancer drivers and guide therapy. Cancer stem cells (CSCs) are a subset of tumor cells with uniquely aggressive, highly tumorigenic, drug resistant properties, which have been shown to mediate cancer recurrence and drug resistance. Dr. Goldkorn’s team has demonstrated that cancer cells can convert in and out of a cancer stem cell phenotype and has elucidated some of the mechanisms that mediate this plasticity, and is studying some of these as potential biomarkers or therapeutic targets. Telomerase is a reverse transcriptase ribonucleoprotein that protects and lengthens telomeres at the ends of chromosomes, and telomerase activation is an essential step in the formation and progression of >90% of all malignancies and therefore constitutes an attractive therapeutic target across multiple malignancies. The Goldkorn Lab has used telomerase interference to reprogram telomerase and kill cancer cells and cancer stem cells in mouse and human-derived models, and is currently developing a novel molecule aimed at delivering telomerase interference as a systemic therapeutic.


UCLA School of Medicine, M.D., 1998


UCLA Medical Center, 1998 - 1999


UCLA Medical Center, 1999 - 2001


UCSF Medical Center, 2002 - 2007


Internal Medicine
Medical Oncology

Professional society memberships:

American Association for Cancer Research
American Society of Clinical Oncology